Results 271 to 280 of about 6,753,495 (314)
Some of the next articles are maybe not open access.
Insomnia and treatment-resistant depression
2023Depression and sleep disturbance are related closely with bidirectional relationship. The heterogenic diagnostic criteria of major depressive disorder composed by the myriad combination of symptoms including sleep disturbance. Insomnia is an identifiable risk factor for depression and the treatment of insomnia might be able to prevent subsequent major ...
Wei-Chen, Lin, John Weyl, Winkelman
openaire +2 more sources
Treatment-resistant depression.
The Journal of clinical psychiatry, 2006info:eu-repo/semantics ...
Souery, Daniel +2 more
openaire +2 more sources
Tinnitus and treatment-resistant depression
2023Tinnitus, a frequent disorder, is the conscious perception of a sound in the absence of a corresponding external acoustic sound source in the sense of a phantom sound. Although the majority of people who perceive a tinnitus sound can cope with it and are only minimaly impaired in their quality of lfe, 2-3% of the population perceive tinnitus as a major
Berthold, Langguth +6 more
openaire +2 more sources
ECT in Treatment-Resistant Depression
American Journal of Psychiatry, 2012Electroconvulsive therapy (ECT), which has been in use for 75 years, is an important treatment for severe and treatment-resistant depression. Although it is acknowledged as the most effective acute treatment for severe mood and psychotic disorders, it remains controversial because of misperceptions about its use and lack of familiarity among health ...
Charles H, Kellner +5 more
openaire +2 more sources
Management of Treatment-Resistant Depression
Psychiatric Clinics of North America, 2012Given the limitations of evidence for treatment options that are consistently effective for TRD and the possibility that TRD is in fact a form of depression that has a low probability of resolving, how can clinicians help patients with TRD? Perhaps the most important conceptual shift that needs to take place before treatment can be helpful is to accept
Gabor I, Keitner, Abigail K, Mansfield
openaire +2 more sources
[Management of treatment resistance-Treatment-resistant schizophrenia].
Der NervenarztDespite a very high prevalence and substantial impairments among affected individuals, treatment-resistant schizophrenia (TRS) has not been sufficiently researched in clinical research in the field of psychiatric disorders and the pathophysiology is still poorly understood.
Elias, Wagner +2 more
openaire +1 more source
Venlafaxine and treatment-resistant depression
Depression and Anxiety, 2000Treatment-resistant depression (TRD) is an important clinical problem. This paper briefly reviews the definition of TRD and summarizes methodological issues that pertain to treatment research. Recent studies of venlafaxine treatment for TRD also are reviewed.
M E, Thase, E S, Friedman, R H, Howland
openaire +2 more sources
The Evaluation of Treatment-Resistant Epilepsy
Seminars in Pediatric Neurology, 2011An estimated 10% to 40% of children with epilepsy have treatment-resistant epilepsy. Persistent seizures have negative psychosocial, behavioral, cognitive, and financial consequences and are associated with an increased mortality rate. Accurate syndromic and etiologic diagnoses are of vital importance because they may guide medical and/or surgical ...
Karen L, Skjei, Dennis J, Dlugos
openaire +2 more sources
Esketamine for treatment resistant depression
Expert Review of Neurotherapeutics, 2019Introduction: Treatment Resistant Depression (TRD) is a common and burdensome condition with poor outcomes and few treatment options. Esketamine is the S-enantiomer of ketamine and has recently been FDA approved in the United States for treating depression that has failed to respond to trials of two or more antidepressants.
Jennifer, Swainson +9 more
openaire +2 more sources
Esketamine for Treatment-Resistant Depression
JAMA PsychiatryTo the Editor Janik et al reported a positive trial of esketamine monotherapy for treatment-resistant depression. However, the lead-in design and functional unblinding could have biased treatment estimates. The 4-week double-blind phase was preceded by a lead-in phase of up to 7 weeks, during which time antidepressant medication was discontinued ...
Cristea I. A., Plöderl M., Naudet F.
openaire +2 more sources